The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II/III, randomized, open-label, multicenter study of BI 907828 compared to doxorubicin in the first-line treatment of patients with advanced dedifferentiated liposarcoma (DDLPS): Brightline-1.
 
Patrick Schöffski
Honoraria - Blueprint Medicines
Consulting or Advisory Role - Adcendo; Blueprint Medicines; Boehringer Ingelheim; Deciphera; Ellipses Pharma; Exelixis; Merck; PharmaMar; SQZ Biotechnology; Studiecentrum voor Kernenergie (SCK CEN); Transgene
Research Funding - CoBioRes NV (Inst); Eisai (Inst); G1 Therapeutics (Inst); Genmab (Inst); Merck (Inst); ONA therapeutics (Inst); PharmaMar (Inst); Sartar Therapeutics (Inst)
 
Scott Schuetze
Consulting or Advisory Role - Adaptimmune; Boehringer Ingelheim
Research Funding - Adaptimmune (Inst); Amgen (Inst); Blueprint Medicines (Inst); GlaxoSmithKline (Inst); Karyopharm Therapeutics (Inst)
 
Javier Martin Broto
Honoraria - Bayer; Eisai; GlaxoSmithKline; Lilly; Novartis; PharmaMar; Tecnofarma
Consulting or Advisory Role - Amgen; Asofarma; Bayer; GlaxoSmithKline; Lilly; Novartis; PharmaMar; Roche; Tecnofarma
Speakers' Bureau - PharmaMar
Research Funding - Amgen (Inst); Bayer (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Eisai; Eisai (Inst); FORMA Therapeutics (Inst); GlaxoSmithKline (Inst); Immix BioPharma (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Lixte Biotechnology (Inst); Nektar (Inst); Novartis; Novartis (Inst); Pfizer (Inst); PharmaMar
Expert Testimony - Novartis; PharmaMar
Travel, Accommodations, Expenses - Pfizer; PharmaMar
 
Andrew J. Wagner
Honoraria - Deciphera
Consulting or Advisory Role - AADi; Boehringer Ingelheim; Cogent Biosciences; Daiichi Sankyo; Deciphera; Epizyme; Lilly; Mundipharma
Research Funding - AADi (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Foghorn Therapeutics (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Plexxikon (Inst); Rain Therapeutics (Inst)
 
Sebastian Bauer
Honoraria - Bayer; Deciphera; GlaxoSmithKline; Novartis; Pfizer; Pharmamar
Consulting or Advisory Role - ADC Therapeutics; Adcendo; Bayer; Blueprint Medicines; Boehringer Ingelheim; Daiichi Sankyo; Deciphera; Exelixis; GlaxoSmithKline; Janssen-Cilag; Lilly; Mundipharma; Nanobiotix
Research Funding - Blueprint Medicines; Incyte (Inst); Novartis
Travel, Accommodations, Expenses - Pharmamar
 
Victoria Chen
Employment - Boehringer Ingelheim
 
Michael Teufel
Employment - Boehringer Ingelheim
 
Anthony Lucarelli
Employment - Boehringer Ingelheim
 
Mehdi Lahmar
Employment - Boehringer Ingelheim
 
Robert G Maki
Consulting or Advisory Role - Bayer; Daiichi Sankyo/Lilly; Deciphera; Ipsen; Karyopharm Therapeutics; PEEL Therapeutics; TRACON Pharma; UpToDate
Speakers' Bureau - PER
Research Funding - Amgen (Inst); Astex Pharmaceuticals (Inst); Bayer (Inst); BioAtla (Inst); Boehringer Ingelheim (Inst); C4 Therapeutics (Inst); Daiichi (Inst); Exelixis (Inst); InhibRx (Inst); PEEL Therapeutics (Inst); Presage Biosciences (Inst); Rain Therapeutics (Inst); Regeneron (Inst); Regeneron (Inst); SARC: Sarcoma Alliance for Research though Collaboration (Inst); SpringWorks Therapeutics (Inst); SynOx (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - Uptodate: I write and edit chapters for their online text book.
Travel, Accommodations, Expenses - SpringWorks Therapeutics; TRACON Pharma